Milsaperidone (VHX-896) vs Paliperidone palmitate (Invega Trinza)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Paliperidone palmitate (Invega Trinza)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule (palmitate ester prodrug, long-acting injectable suspension)
Weak signal

NCT02713282 · Phase 3 · completed

This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)

Result source: NCT04072575

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Paliperidone palmitate (Invega Trinza)
PANSS total, change—Not reported-1.8 vs -1.6vs PP3Mwk 52 · n 473NCT03345342
CGI-S, change—Not reported0 vs 0vs PP3Mwk 52 · n 475NCT03345342
2 other results
PANSS response—Not reported—Not posted · NCT02713282
PSP, change—Not reported1 vs 1.1vs PP3Mwk 52 · n 473NCT03345342
2 other results
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
Relapse (% of patients)—Not reported—Not posted · NCT02713282

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Trinza)
-1.8 vs -1.6vs PP3Mwk 52 · n 473NCT03345342

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Trinza)
0 vs 0vs PP3Mwk 52 · n 475NCT03345342
2 other results

PANSS response

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Trinza)
—Not posted · NCT02713282

PSP, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Trinza)
1 vs 1.1vs PP3Mwk 52 · n 473NCT03345342
2 other results
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Trinza)
—Not posted · NCT02713282
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Paliperidone palmitate (Invega Trinza): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPaliperidone palmitate (Invega Trinza)
Dropout rate
—Double-blind PP6Ma
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
13.5%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
—
NCT01529515 · Phase 3
—Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—Double-blind PP6Ma
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
3.9%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
—
NCT01529515 · Phase 3
—Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Serious AEs
5%Double-blind PP6Ma
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
5.5%Follow-up Phase PP6M
NCT03345342 · Phase 3 · Schizophrenia · phase 3
4.5%700 or 1000 mg eq
NCT04072575 · Phase 3 · combination
2.5%
NCT01529515 · Phase 3
12.8%Part 2-Paliperidone Palmitate (PP)
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
5.3%Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3 · registry result, not featured evidence
2%Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
weight increased 8.4%
injection site pain 7.7%
headache 6.7%
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 6 more results
nasopharyngitis 3.7%
upper respiratory tract infection 0.9%
headache 0%
NCT03345342 · Phase 3 · Schizophrenia · phase 3
700 or 1000 mg eq
headache 13.5%
blood prolactin increased 10.7%
hyperprolactinaemia 7.3%
NCT04072575 · Phase 3 · combination
headache 8.8% (placebo 4.1%)
weight increased 8.8% (placebo 3.4%)
anxiety 8.1% (placebo 10.3%)
NCT01529515 · Phase 3
weight increased 28.2%
akathisia 9%
headache 9%
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
weight increased 15.8%
anxiety 10.5%
insomnia 10.5%
NCT02431702 · Phase 3 · registry result, not featured evidence
weight increased 14.3%
insomnia 10.2%
nasopharyngitis 6.1%
NCT02431702 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Paliperidone palmitate (Invega Trinza)

Time to Relapse NA vs NA PP3M months @ 52wk
time to event · months
NCT03345342 · Phase 3 · Schizophrenia · phase 3
PANSS Total -1.8 vs -1.6 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
CGI-S 0 vs 0 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 2 more results
-0.2 vs -0.3 Oral Antipsychotics score
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
-0.7 vs -0.7 Oral Antipsychotics score
NCT02431702 · Phase 3 · registry result, not featured evidence
PSP 1 vs 1.1 PP3M score @ 52wk
absolute change · score
NCT03345342 · Phase 3 · Schizophrenia · phase 3
show 2 more results
2.5 vs 2.9 Oral Antipsychotics score @ 39.1wk
NCT02431702 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 7 Oral Antipsychotics score @ 78.2wk
NCT02431702 · Phase 3 · registry result, not featured evidence
Symptomatic Remission 66.3% (n=478) vs 70.1% (n=224) PP3M @ 52wk
responder rate · % of participants
NCT03345342 · Phase 3 · Schizophrenia · phase 3
Relapse 3.9% (n=178) @ 104wk700 or 1000 mg eq
event count · % of participants
No placebo or comparator arm
NCT04072575 · Phase 3 · combination · converted to % from 7 Participants as posted
CGI-S 0 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
PSP 0.5 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
PANSS Total 0.7 score @ 104wk700 or 1000 mg eq
absolute change · score
No placebo or comparator arm
NCT04072575 · Phase 3 · combination
Time to Relapse Median NA vs 12.98 placebo months @ 60wk
time to event · months
NCT01529515 · Phase 3
PANSS Total -0.5 vs 6.7 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3
CGI-S 0.1 vs 0.4 placebo score @ 60wk
absolute change · score
Change at Endpoint (Approximately Week 60)
NCT01529515 · Phase 3

+ 11 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Paliperidone palmitate (Invega Trinza)'s landscape